A Retrospective Study of Cemiplimab Effectiveness in Elderly Patients with Squamous Cell Carcinoma of the Skin: Insights from a Real-Life Scenario.
Adverse reactions
Cemiplimab
Clinical response
Distant metastasis
Squamous cell carcinoma
Survival outcomes
Journal
Oncology and therapy
ISSN: 2366-1089
Titre abrégé: Oncol Ther
Pays: New Zealand
ID NLM: 101677510
Informations de publication
Date de publication:
19 Dec 2023
19 Dec 2023
Historique:
received:
28
09
2023
accepted:
01
12
2023
medline:
19
12
2023
pubmed:
19
12
2023
entrez:
19
12
2023
Statut:
aheadofprint
Résumé
This retrospective study investigates the efficacy of cemiplimab, a monoclonal antibody targeting the PD-1 receptor, in treating squamous cell carcinoma (SCC) of the skin. The study analyzes data from 50 patients with SCC, focusing on various clinical parameters, including patient demographics, tumor characteristics, treatment history, disease status at the beginning of therapy, and survival outcomes. Of the patients who received at least one cycle of cemiplimab, 42% showed a clinical response. Adverse reactions were generally low, with the safety profile deemed excellent. During a median follow-up of 9.6 months, 17 patients experienced progression or death. Among these, 15 patients had died at the time of the analysis. The median progression-free survival (PFS) for the entire cohort was approximately 20.8 months, while median overall survival (OS) was not reached. Univariate Cox regression analysis for PFS showed that tumors in the arms and legs were associated with higher progression risk, while age above 65 years was not statistically significant. Distant metastasis exhibited a trend towards improved PFS. In terms of OS, distant metastasis was a significant predictor of reduced survival, while age above 65 years was not statistically significant. In a multivariate model, only the absence of distant metastasis remained significant, with an adjusted odds ratio (OR) of 12.3 (95% confidence interval 1.3-112.1). These findings provide valuable insights into the real-world effectiveness of cemiplimab in SCC management.
Identifiants
pubmed: 38112965
doi: 10.1007/s40487-023-00256-1
pii: 10.1007/s40487-023-00256-1
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2023. The Author(s).
Références
Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol. 2015;151:1081. https://doi.org/10.1001/jamadermatol.2015.1187 .
doi: 10.1001/jamadermatol.2015.1187
pubmed: 25928283
Wysong A. Squamous-cell carcinoma of the skin. N Engl J Med. 2023;388:2262–73. https://doi.org/10.1056/NEJMra2206348 .
doi: 10.1056/NEJMra2206348
pubmed: 37314707
Hillen U, Leiter U, Haase S, et al. Advanced cutaneous squamous cell carcinoma: a retrospective analysis of patient profiles and treatment patterns—results of a non-interventional study of the DeCOG. Eur J Cancer. 2018;96:34–43. https://doi.org/10.1016/j.ejca.2018.01.075 .
doi: 10.1016/j.ejca.2018.01.075
pubmed: 29665511
Goodman DT. Cemiplimab and cutaneous squamous cell carcinoma: from bench to bedside. JPRAS Open. 2022;33:155–60. https://doi.org/10.1016/j.jpra.2022.06.003 .
doi: 10.1016/j.jpra.2022.06.003
pubmed: 36046255
pmcid: 9421083
Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379:341–51. https://doi.org/10.1056/NEJMoa1805131 .
doi: 10.1056/NEJMoa1805131
pubmed: 29863979
Bailly-Caillé B, Kottler D, Morello R, et al. real-life study of the benefit of concomitant radiotherapy with cemiplimab in advanced cutaneous squamous cell carcinoma (cSCC): a retrospective cohort study. Cancers (Basel). 2023;15:495. https://doi.org/10.3390/cancers15020495 .
doi: 10.3390/cancers15020495
pubmed: 36672444
Migden MR, Schmults C, Khushanlani N, et al. 814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3. Ann Oncol. 2022;33:S918–9. https://doi.org/10.1016/j.annonc.2022.07.940 .
doi: 10.1016/j.annonc.2022.07.940
Denaro N, Passoni E, Indini A, et al. Cemiplimab in ultra-octogenarian patients with cutaneous squamous cell carcinoma: the real-life experience of a tertiary referral center. Vaccines (Basel). 2023;11:1500. https://doi.org/10.3390/vaccines11091500 .
doi: 10.3390/vaccines11091500
pubmed: 37766176
Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020;21:294–305. https://doi.org/10.1016/S1470-2045(19)30728-4 .
doi: 10.1016/S1470-2045(19)30728-4
pubmed: 31952975
pmcid: 7771329
Baggi A, Quaglino P, Rubatto M, et al. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. Eur J Cancer. 2021;157:250–8. https://doi.org/10.1016/j.ejca.2021.08.018 .
doi: 10.1016/j.ejca.2021.08.018
pubmed: 34536948
Gross ND, Miller DM, Khushalani NI, et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med. 2022;387:1557–68. https://doi.org/10.1056/NEJMoa2209813 .
doi: 10.1056/NEJMoa2209813
pubmed: 36094839
pmcid: 9844515
Mallardo D, Simeone E, Festino L, et al. IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab. J Transl Med. 2023;21:140. https://doi.org/10.1186/s12967-023-03971-5 .
doi: 10.1186/s12967-023-03971-5
pubmed: 36823670
pmcid: 9948392
Maubec E, Boubaya M, Petrow P, et al. Phase II study of pembrolizumab as first-line, single-drug therapy for patients with unresectable cutaneous squamous cell carcinomas. J Clin Oncol. 2020;38:3051–61. https://doi.org/10.1200/JCO.19.03357298 .
doi: 10.1200/JCO.19.03357298
pubmed: 32730186